Nature Biotechnology

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

Retrieved on: 
Lunedì, Aprile 22, 2024
Bone marrow, FQR, CRISPR, Nature Biotechnology, Safety, Education, Pharmacokinetics, Infection, Neutropenia, Survival, AMR, Febrile neutropenia, Gene editing, Partnership, Bloodstream infections, Development, BMBF, Escherichia coli, Research and development, Patient, Quinolone antibiotic, Synthetic biology, HSCT, Pharmaceutical industry

Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.

Key Points: 
  • Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
  • Despite the significant advances in hematologic cancer therapy over the past decade, infectious complications, and antimicrobial resistance (AMR) continue to pose significant threats to patients and clinical outcomes1.
  • Currently, there are no approved therapies for the prevention of bloodstream infections (BSIs) in hematological cancer patients.
  • SNIPR Biome is developing SNIPR001 to address this urgent unmet need to combat infections in hematological cancer patients.

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

Retrieved on: 
Lunedì, Aprile 22, 2024
Bone marrow, FQR, CRISPR, Nature Biotechnology, Safety, Education, Pharmacokinetics, Infection, Neutropenia, Survival, AMR, Febrile neutropenia, Gene editing, Partnership, Bloodstream infections, Development, BMBF, Escherichia coli, Research and development, Patient, Quinolone antibiotic, Synthetic biology, HSCT, Pharmaceutical industry

Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.

Key Points: 
  • Fluoroquinolone is recommended in the US for prophylaxis of bacterial infections and febrile neutropenia in hematological cancer patients at high risk of neutropenia.
  • Despite the significant advances in hematologic cancer therapy over the past decade, infectious complications, and antimicrobial resistance (AMR) continue to pose significant threats to patients and clinical outcomes1.
  • Currently, there are no approved therapies for the prevention of bloodstream infections (BSIs) in hematological cancer patients.
  • SNIPR Biome is developing SNIPR001 to address this urgent unmet need to combat infections in hematological cancer patients.

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Martedì, Aprile 30, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Nature Biotechnology, Compensated emancipation, Virology, Research, Employment, Medication, Pharmaceutical industry

The 2024 Inducement Stock Incentive Plan has been adopted by the Board of Directors to be used exclusively for the grant of equity awards to any individual who was not previously an employee or non-employee director of Enanta Pharmaceuticals, as an inducement material to such individual's entering into employment with Enanta Pharmaceuticals, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Key Points: 
  • The 2024 Inducement Stock Incentive Plan has been adopted by the Board of Directors to be used exclusively for the grant of equity awards to any individual who was not previously an employee or non-employee director of Enanta Pharmaceuticals, as an inducement material to such individual's entering into employment with Enanta Pharmaceuticals, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The stock option granted to Mr. Kowalsky has an exercise price equal to the closing price of Enanta Pharmaceuticals’ common stock on April 29, 2024.
  • In each case the benefit of the PSUs and rTSRUs is subject to the unit holder’s continued employment on the settlement date in February 2026.
  • The option and units are subject to the terms and conditions of Enanta Pharmaceuticals' 2024 Inducement Stock Incentive Plan and the respective terms and conditions of the stock option and unit agreements covering these awards.

RootPath Announces Publication Demonstrating How Its Novel Gene Synthesis Technology Empowers Cell Therapy in Solid Tumor Cancers

Retrieved on: 
Martedì, Aprile 23, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Nature Medicine, NKI, Cell, Nature Biotechnology, TILS, Research, Patient, Netherlands Cancer Institute, Synthetic biology, Discovery, Neoplasm, TCR, Growth, Gene, Fine chemical

RootPath , a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced a new publication in Nature Biotechnology detailing research that demonstrates the power of the company’s novel gene synthesis technology and how it may contribute to successful cell therapy in solid tumor cancers.

Key Points: 
  • RootPath , a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced a new publication in Nature Biotechnology detailing research that demonstrates the power of the company’s novel gene synthesis technology and how it may contribute to successful cell therapy in solid tumor cancers.
  • The publication is titled “ Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening ”.
  • With the help of RootPath’s innovative synthesis technology, we now improved the throughput of this approach by a factor of 100.
  • The company will soon offer TCR gene synthesis and screening services commercially, as reported in the study.

Seed Health Appoints Microbiome Pioneer Zain Kassam, M.D., M.P.H., as Chief Medical Officer

Retrieved on: 
Mercoledì, Aprile 24, 2024
Western University, Harvard University, Nature Biotechnology, Public health, Chairperson, Abstract, Health, McMaster University, OpenBiome, FMT, Janssen, IPO, Therapy, Science, Ecology, Alumni, Internal medicine, Bacillota, Longevity, Growth, MIT, Medical device

BOSTON, April 24, 2024 /PRNewswire/ -- Seed Health, a microbiome science company, today announced the appointment of Zain Kassam, M.D., M.P.H., as Chief Medical Officer. An award-winning physician-scientist, Dr. Kassam has played a pivotal role in the advancement of microbiome science for over a decade. His extensive body of work includes over 200 peer-reviewed publications and abstracts, including in The New England Journal of Medicine, Nature Biotechnology, and Gastroenterology, and co-authoring international clinical practice guidelines. He has championed more than 30 Phase I-III clinical trials with top-tier academic institutions across multiple therapeutic areas. As Chief Medical Officer, Dr. Kassam will collaborate with Chief Scientific Officer, Dirk Gevers, Ph.D., to oversee Seed Health's R&D portfolio. He will expand the company's gut microbiome program and guide upcoming launches in the vaginal and skin microbiome sectors, as well as in brain health, metabolic health, and longevity.

Key Points: 
  • Dr. Kassam will lead Seed Health's clinical research and medical affairs, driving the
    BOSTON, April 24, 2024 /PRNewswire/ -- Seed Health , a microbiome science company, today announced the appointment of Zain Kassam, M.D., M.P.H., as Chief Medical Officer.
  • As Chief Medical Officer, Dr. Kassam will collaborate with Chief Scientific Officer, Dirk Gevers, Ph.D., to oversee Seed Health's R&D portfolio.
  • He will expand the company's gut microbiome program and guide upcoming launches in the vaginal and skin microbiome sectors, as well as in brain health, metabolic health, and longevity.
  • Before joining Seed Health, Dr. Kassam co-founded and was Chief Medical Officer at two foundational microbiome therapeutics companies, OpenBiome and Finch Therapeutics.

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Retrieved on: 
Mercoledì, Aprile 10, 2024
Notifiable disease, Metabolism, Obesity, Euronext Growth, Skeletal muscle, Patient, Nature Biotechnology, Weight loss, Trial of the century, OBA, Facial muscles, Sarcopenia, Therapy, MAS, Pharmaceutical industry

These benefical effects of BIO101 (20-hydroxyecdysone) may translate into improved mobility and muscle strength in obese sarcopenic patients, as suggested in the SARA-INT phase 2 study.

Key Points: 
  • These benefical effects of BIO101 (20-hydroxyecdysone) may translate into improved mobility and muscle strength in obese sarcopenic patients, as suggested in the SARA-INT phase 2 study.
  • We believe that our leadership in developing drugs for muscular diseases and promising results obtained in obesity will be a strong accelerator of the OBA clinical plan."
  • The OBA Phase 2 clinical study is expected to start mid 2024, upon regulatory approvals, with first patients expected to be treated in the second half of 2024.
  • Further information on the OBA program and the clinical study is expected to be provided through the coming weeks.

Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

Retrieved on: 
Lunedì, Aprile 8, 2024
AP, Infection, HIV, Nature Biotechnology, Epitope, Cancer, SARS-CoV-2, Gritstone bio, HLA, AACR, Immunity, EDGE, Poster, Vaccine

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an update on its T cell epitope discovery platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 (Nature Biotechnology). It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.

Key Points: 
  • The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 ( Nature Biotechnology ).
  • It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.
  • “Identifying which of the hundreds of tumor mutations are most likely to serve as neoantigens, key targets of tumor-specific T cells, is critical to the development of effective neoantigen-directed vaccines,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio.
  • The improvements we are making to EDGE, leveraging advances in protein large language models and in-house immunopeptidomics, have positioned EDGE as a leading HLA/peptide predictive platform in the neoantigen cancer vaccine field.

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines

Retrieved on: 
Martedì, Aprile 9, 2024
Research, Medical Supplies, Infectious Diseases, Genetics, Biotechnology, Other Health, Health, Pharmaceutical, Science, Culture, Broad Institute, Cell, Massachusetts General Hospital, Partner (business rank), Environment, Trust, RNP, MIT, Spark Therapeutics, Patient, Harvard University, Nature Biotechnology, Tissue, Head, Protein, Therapy, Former, Safety, Royal Naval Patrol Service, FDA, Management

Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.

Key Points: 
  • Nvelop Therapeutics , a biotechnology company engineering programmable, non-viral vehicles for the in vivo delivery of therapeutic cargo, today formally announced its launch to develop the next generation of genetic medicines for a wide range of diseases.
  • The company’s approach has the potential to enable highly efficient and cell-specific delivery of a broad set of therapeutic cargoes.
  • “The field of genetic medicine is significantly limited by the challenge of efficiently delivering therapeutic cargoes to many types of target cells in vivo,” said Jeff Walsh, Nvelop’s Chief Executive Officer.
  • In vivo data for the second platform is expected to be disclosed at one or more scientific meetings this year.

Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

Retrieved on: 
Giovedì, Marzo 21, 2024
Deflation, Climate change, Taste, Biotechnology, Plural, Cell, International, Coffee, Nature Biotechnology, ICO, Water, Heat, Frost, PLUR, Maxwell House International, Report, Weather

Price instability and cost increases will impact coffee drinkers worldwide, as more than 2 billion cups of coffee are drunk each day, 400 million of them by Americans.

Key Points: 
  • Price instability and cost increases will impact coffee drinkers worldwide, as more than 2 billion cups of coffee are drunk each day, 400 million of them by Americans.
  • Pluri’s cell-based coffee aims to reduce price instability by moving coffee production into the lab, eliminating the effect of climate change and adverse weather conditions.
  • Pluri recently announced the launch of its cell-based coffee , its proprietary cultured coffee product business, part of its PluriAgtech vertical, addressing the $130 billion coffee industry.
  • To learn more about Pluri’s coffee see the recent article titled “Cell-Based Coffee Future-Proofs World’s Favorite Brew” in the leading peer-reviewed journal Nature Biotechnology.

Profluent Secures $35M in Additional Funding and Key Industry Experts to Scale Foundational AI Models for Biomedicine and Tackle First Vertical in Gene Editing

Retrieved on: 
Giovedì, Marzo 21, 2024
Other Health, Software, Research, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Other Science, Health, AIX, Cas9, OpenAI, Gene editing, Insight Partners, Growth, Spotlight, General partnership, Salesforce, Nature Biotechnology, Gene, Spark Capital, AI, University, Tome, Nature, Protein engineering, Biology, Microbiology, CRISPR, De novo, ChatGPT, Therapy, Machine learning, Probability, Management

Profluent, an AI-first protein design company, today announced the close of additional funding to bring the total raised to $44M.

Key Points: 
  • Profluent, an AI-first protein design company, today announced the close of additional funding to bring the total raised to $44M.
  • “Our research at the forefront of AI has enabled Profluent to create large language models that begin to learn the blueprint of nature,” said Ali Madani, Profluent co-founder and Chief Executive Officer.
  • By first applying its platform to gene editing, the company showcases AI as the ideal interface for engineering complex biological systems.
  • Just as ChatGPT can write compelling essays and emails, Profluent has developed AI that designs entirely new and functional proteins.